Cannabigerovarin (CBGV) Cannabinoid Research

Description of Cannabigerovarin (CBGV)

CBGV (Cannabigerovarin) was first isolated and identified in the mid-seventies (Y. Shoyama et al., 1975) who extracted it from a Thai strain (Meao) of Cannabis sativa using chromatographic techniques. This discovery was part of broader research into varin-type cannabinoids, which are characterized by a shorter three-carbon (propyl) side chain, compared to the more common five-carbon (pentyl) side chain found in cannabinoids like CBG. The identification of CBGV contributed to the expanding understanding of the chemical diversity within the cannabis plant and laid the groundwork for subsequent studies into its potential pharmacological properties.

CBGV is the neutral (decarboxylated) form of CBGVA (Cannabigerovarinic acid), which is the acidic precursor produced by the plant. During heating or aging, CBGVA naturally converts into CBGV through decarboxylation—a process similar to how THCA becomes THC or CBDA becomes CBD.

Cannabigerovarin (CBGV) is found in trace amounts in the cannabis plant and is closely related to Cannabigerol (CBG), often called the “mother cannabinoid” because it helps form many other cannabinoids during the plant’s growth.

Like CBG, CBGV is non-intoxicating, meaning it doesn’t cause changes in cognition. Although it’s found in smaller amounts, early research suggests that CBGV may have potential therapeutic benefits, particularly in areas like inflammation, skin health, as a supportive compound in topical formulations, and cancer.